SARAH SOBOTKA: Open Payments
NPI 1063897213 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$686 in 32 payments from 8 companies in 2025. Trend: 2023 $395 · 2024 $542 · 2025 $686
Food & beverage: $686
| Company | Payments | Amount |
|---|---|---|
| Sumitomo Pharma America, Inc. | 9 | $208 |
| Astellas Pharma US Inc | 8 | $187 |
| Biogen, Inc. | 5 | $85 |
| MAYNE PHARMA COMMERCIAL LLC | 4 | $82 |
| Exeltis, USA Inc. | 3 | $44 |
| CooperSurgical, Inc. | 1 | $37 |
| Octapharma USA, Inc. | 1 | $25 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $17 |
Products named: MYFEMBREE, Veozah, ZURZUVAE, SLYND, Paragard T 380A, FIBRYGA, Lynkuet.
Industry payments across NE — which companies pay providers there.
